Enhanced Prediction of HER2 Status in Breast Cancer through the Integration of Intratumoral and Peritumoral Radiomic Features from DCE-MRI - Takeaways - MDSpire

Enhanced Prediction of HER2 Status in Breast Cancer through the Integration of Intratumoral and Peritumoral Radiomic Features from DCE-MRI

  • By

  • Yang Gao

  • Jiangnian Gong

  • Yuanling Yang

  • Yingyi Luo

  • Weiyi Liu

  • Zisan Zeng

  • February 13, 2026

  • 0 min

Share

  • 1

    HER2 status is crucial for breast cancer treatment and prognosis, influencing the use of targeted therapies such as monoclonal antibodies and ADCs.

  • 2

    The 2018 ASCO/CAP guidelines introduced HER2-low as a distinct subtype, highlighting its clinical relevance and potential as a therapeutic target.

  • 3

    Current methods for assessing HER2 status, like IHC and FISH, are invasive and may under-detect HER2-low expression due to tumor heterogeneity.

  • 4

    This study aims to develop a prediction model for HER2 expression using intratumoral and peritumoral radiomic features from DCE-MRI.

  • 5

    A total of 210 eligible breast cancer patients were included in the study, following strict inclusion and exclusion criteria for data analysis.

Original Source(s)

Enhanced Prediction of HER2 Status in Breast Cancer through the Integration of Intratumoral and Peritumoral Radiomic Features from DCE-MRI

  • by Yang Gao, Jiangnian Gong, Yuanling Yang, Yingyi Luo, Weiyi Liu, Zisan Zeng

  • February 13, 2026

Related Content

MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

High risk score of breast cancer by artificial intelligence (AI) on screening mammograms: a review of negative and cancer cases